BMC Cancer : Impact Factor & More
eISSN: 1471-2407pISSN: 1471-2407
Open AccessShare this on:
Aims and Scope of BMC Cancer
BMC Cancer is a peer-reviewed open access medical journal that publishes original research on cancer and oncology. It was established in 2001 and is published by BioMed Central.
Key Metrics
CiteScore 
6.7
Eigenfactor
0.05 - 0.1
Impact Factor
< 5
Scite Index
0.88 5-Year SI
SJR
Q2Genetics
SNIP
1.31
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on BMC Cancer
BMC Cancer Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
DOAJ 
SJR
| Overview | |
| Publisher | BMC |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | GBP 2190 | USD 2990 | EUR 2590 |
| Publication Time | 19 |
| Editorial Review Process | Open peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2001 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC0 |
| OA statement | Visit website |
View less
Planning to publish in BMC Cancer ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in BMC Cancer
Retraction Note: The role of c-Src in the invasion and metastasis of hepatocellular carcinoma cells induced by association of cell surface GRP78 with activated α2M.
- 8 Aug 2026
- BMC cancer
Retraction Note: Blockage of AMPK-ULK1 pathway mediated autophagy promotes cell apoptosis to increase doxorubicin sensitivity in breast cancer (BC) cells: an in vitro study.
- 8 Aug 2026
- BMC cancer
Retraction Note: Development and validation of genomic and epigenomic signatures associated with tumor immune microenvironment in hepatoblastoma
- 5 Aug 2026
- BMC Cancer
DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy
- 5 Aug 2026
- BMC Cancer
Precision oncology meets Generative AI: assessing large language models in multidisciplinary GIST tumor boards
- 1 Aug 2026
- BMC Cancer
Correction: Four-year follow-up from the phase 2 study TD-NICE: neoadjuvant treatment of tislelizumab combined with chemotherapy in resectable esophageal squamous cell carcinoma
- 1 Aug 2026
- BMC Cancer
Retraction Note: The role of c-Src in the invasion and metastasis of hepatocellular carcinoma cells induced by association of cell surface GRP78 with activated α2M.
- 8 Aug 2026
- BMC cancer
Retraction Note: Blockage of AMPK-ULK1 pathway mediated autophagy promotes cell apoptosis to increase doxorubicin sensitivity in breast cancer (BC) cells: an in vitro study.
- 8 Aug 2026
- BMC cancer
Retraction Note: Development and validation of genomic and epigenomic signatures associated with tumor immune microenvironment in hepatoblastoma
- 5 Aug 2026
- BMC Cancer
DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy
- 5 Aug 2026
- BMC Cancer
Precision oncology meets Generative AI: assessing large language models in multidisciplinary GIST tumor boards
- 1 Aug 2026
- BMC Cancer
Correction: Four-year follow-up from the phase 2 study TD-NICE: neoadjuvant treatment of tislelizumab combined with chemotherapy in resectable esophageal squamous cell carcinoma
- 1 Aug 2026
- BMC Cancer
FAQs on BMC Cancer
How long has BMC Cancer been actively publishing? 
What is the publishing frequency of BMC Cancer?
How many articles did BMC Cancer publish last year?
What is the eISSN & pISSN for BMC Cancer?
What is Citescore for BMC Cancer?
What is SNIP score for BMC Cancer?
What is the SJR for BMC Cancer?
Who is the publisher of BMC Cancer?
Check if your manuscript is a good match for
undefined
Upload your manuscript to get recommendations of journals
that have published papers similar to your manuscript
Drag and drop your file here
We accept manuscripts in English. File format: .doc and .docx | Maximum size: 10 MB | Word count: 200-300,000 words | File length: less than 100 pages
Do not have a manuscript right now? Use an abstract or summary
Your document is 100% secure & confidential We use 256-bit encryption for total security and
ISO/IEC 27001:2022 Certified
What all does the report include
01. Degree of Match
02. Common Topics
03. Additional
Recommendations
Recommendations